Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology.
+ 1 more risk
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has Zosano Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZSAN's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ZSAN underperformed the US Medical Equipment industry which returned 15.5% over the past year.
Return vs Market: ZSAN underperformed the US Market which returned 16.3% over the past year.
Price Volatility Vs. Market
How volatile is Zosano Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StRead This Before Selling Zosano Pharma Corporation (NASDAQ:ZSAN) Shares
8 months ago | Simply Wall StNeed To Know: Zosano Pharma Corporation (NASDAQ:ZSAN) Insiders Have Been Buying Shares
11 months ago | Simply Wall StDo Directors Own Zosano Pharma Corporation (NASDAQ:ZSAN) Shares?
Is Zosano Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ZSAN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ZSAN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ZSAN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: ZSAN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZSAN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ZSAN is overvalued based on its PB Ratio (4.8x) compared to the US Medical Equipment industry average (3.9x).
How is Zosano Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZSAN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZSAN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZSAN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ZSAN's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ZSAN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ZSAN's Return on Equity is forecast to be high in 3 years time
How has Zosano Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZSAN is currently unprofitable.
Growing Profit Margin: ZSAN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZSAN is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.
Accelerating Growth: Unable to compare ZSAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZSAN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).
Return on Equity
High ROE: ZSAN has a negative Return on Equity (-191.65%), as it is currently unprofitable.
How is Zosano Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ZSAN's short term assets ($11.2M) do not cover its short term liabilities ($16.5M).
Long Term Liabilities: ZSAN's short term assets ($11.2M) do not cover its long term liabilities ($12.7M).
Debt to Equity History and Analysis
Debt Level: ZSAN's debt to equity ratio (8.7%) is considered satisfactory.
Reducing Debt: ZSAN's debt to equity ratio has reduced from 35.8% to 8.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZSAN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ZSAN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Zosano Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZSAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZSAN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZSAN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZSAN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZSAN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steven Lo (53 yo)
Mr. Steven Lo has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive Officer since October 21, 2019. Mr. Lo served as Chief Commercial Officer of ...
CEO Compensation Analysis
Compensation vs Market: Steven's total compensation ($USD874.64K) is above average for companies of similar size in the US market ($USD593.36K).
Compensation vs Earnings: Insufficient data to compare Steven's compensation with company performance.
|Vice President of Clinical Development & Medical Affairs||5.17yrs||US$420.85k||0.0015% |
|Chief Financial Officer||0.50yr||no data||no data|
|Senior Vice President of Operations||3.08yrs||US$781.73k||0.00044% |
|Secretary||no data||no data||no data|
Experienced Management: ZSAN's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
|Independent Director||2.83yrs||US$57.90k||0.018% |
|Independent Director||1.58yrs||US$96.19k||no data|
|Independent Director||2.25yrs||US$47.90k||0.00050% |
|Independent Director||7.33yrs||US$54.89k||0.0020% |
|Independent Director||5.25yrs||US$57.89k||no data|
Experienced Board: ZSAN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 206.7%.
Zosano Pharma Corporation's company bio, employee growth, exchange listings and data sources
- Name: Zosano Pharma Corporation
- Ticker: ZSAN
- Exchange: NasdaqCM
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$84.804m
- Shares outstanding: 54.36m
- Website: https://www.zosanopharma.com
Number of Employees
- Zosano Pharma Corporation
- 34790 Ardentech Court
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ZSAN||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jan 2015|
|0ZPN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2015|
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its l ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/09 23:32|
|End of Day Share Price||2020/08/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.